{"id":"pq-unsupervised","safety":{"commonSideEffects":[{"rate":null,"effect":"Hemolysis in G6PD-deficient patients"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Methemoglobinemia"}]},"_chembl":{"chemblId":"CHEMBL439259","moleculeType":"Small molecule","molecularWeight":"341.80"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Primaquine is an 8-aminoquinoline that acts as a prodrug, requiring hepatic metabolism to generate active metabolites that damage the mitochondria of hypnozoites in hepatocytes. This mechanism prevents relapse malaria by eliminating the reservoir of dormant parasites that can reactivate weeks to months after the initial blood-stage infection is cleared. The 'unsupervised' formulation is designed for use without direct medical supervision, improving accessibility in resource-limited settings.","oneSentence":"PQ unsupervised is a primaquine-based antimalarial that eliminates dormant liver stages (hypnozoites) of Plasmodium vivax and P. ovale malaria parasites.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:02:00.264Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Radical cure of Plasmodium vivax malaria (hypnozoite elimination)"},{"name":"Radical cure of Plasmodium ovale malaria (hypnozoite elimination)"}]},"trialDetails":[{"nctId":"NCT04411836","phase":"PHASE3","title":"Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2021-04-25","conditions":"Vivax Malaria, Plasmodium Vivax, Malaria, Vivax","enrollment":960},{"nctId":"NCT02787070","phase":"PHASE4","title":"A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2016-09-14","conditions":"Uncomplicated Malaria","enrollment":420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PQ unsupervised","genericName":"PQ unsupervised","companyName":"Menzies School of Health Research","companyId":"menzies-school-of-health-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PQ unsupervised is a primaquine-based antimalarial that eliminates dormant liver stages (hypnozoites) of Plasmodium vivax and P. ovale malaria parasites. Used for Radical cure of Plasmodium vivax malaria (hypnozoite elimination), Radical cure of Plasmodium ovale malaria (hypnozoite elimination).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}